{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:37:00Z","timestamp":1793371020099,"version":"4.5.0"},"reference-count":140,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jaad.2026.08.086","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:42:48Z","timestamp":1787848968000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comorbidity-guided management of pyoderma gangrenosum: A clinical guide to emerging therapeutic targets"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3180-8876","authenticated-orcid":false,"given":"Houriah Y.","family":"Nukaly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk M.","family":"Elston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2026.08.086_bib1","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v104.42018","article-title":"Living with pyoderma gangrenosum: a qualitative Study","volume":"104","author":"Jiang","year":"2024","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2026.08.086_bib2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jamadermatol.2022.5437","article-title":"Association of all-cause and cause-specific mortality risks with pyoderma Gangrenosum","volume":"159","author":"Lee","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.08.086_bib3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000536145","article-title":"Mortality and autopsy findings in patients with pyoderma gangrenosum: a multi-institutional series","volume":"240","author":"Shakshouk","year":"2024","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.jaad.2026.08.086_bib4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40257-018-0356-7","article-title":"Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta-analysis","volume":"19","author":"Kridin","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2026.08.086_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/clinpract15030057","article-title":"Pyoderma gangrenosum in a patient with Crohn's Disease treated with adalimumab: a case-based review and systematic review of the Current literature","volume":"15","author":"Fousekis","year":"2025","journal-title":"Clin Pract"},{"issue":"4","key":"10.1016\/j.jaad.2026.08.086_bib6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jamadermatol.2017.5978","article-title":"The Association of Age with clinical presentation and comorbidities of pyoderma Gangrenosum","volume":"154","author":"Ashchyan","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2026.08.086_bib7","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1093\/ibd\/izy174","article-title":"Pyoderma gangrenosum: a review for the gastroenterologist","volume":"24","author":"Plumptre","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.jaad.2026.08.086_bib8","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1007\/s10620-013-2762-2","article-title":"Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease","volume":"58","author":"Arg\u00fcelles-Arias","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jaad.2026.08.086_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2026.04.1968","article-title":"Initial development and pragmatic clinical validation of a static disease severity instrument for pyoderma gangrenosum: investigator Global Assessment for PG (IGAPg)","author":"Jacobson","year":"2026","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2026.08.086_bib10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40257-022-00699-8","article-title":"Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments","volume":"23","author":"Maronese","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"14","key":"10.1016\/j.jaad.2026.08.086_bib11","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-023-01931-3","article-title":"Pyoderma gangrenosum: treatment options","volume":"83","author":"Dissemond","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2026.08.086_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2958","article-title":"Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial","volume":"350","author":"Ormerod","year":"2015","journal-title":"Bmj"},{"issue":"8","key":"10.1016\/j.jaad.2026.08.086_bib13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00403-024-03332-2","article-title":"Use of biologic therapies in the management of pyoderma gangrenosum: a systematic review","volume":"316","author":"Zaman","year":"2024","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"10.1016\/j.jaad.2026.08.086_bib14","first-page":"290","article-title":"Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials","volume":"179","author":"Partridge","year":"2018","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.08.086_bib15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.det.2023.12.002","article-title":"Treatment of Pyoderma Gangrenosum","volume":"42","author":"Tan","year":"2024","journal-title":"Dermatol Clin"},{"issue":"1","key":"10.1016\/j.jaad.2026.08.086_bib16","first-page":"32","article-title":"Biologics and immunoglobulins in the treatment of pyoderma gangrenosum - analysis of 52 patients","volume":"17","author":"Herberger","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"10.1016\/j.jaad.2026.08.086_bib17","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.abd.2024.07.014","article-title":"Pyoderma gangrenosum: a 22-year follow-up of patients in a tertiary reference hospital in Brazil","volume":"100","author":"Salviano","year":"2025","journal-title":"An Bras Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.08.086_bib18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0190-9622(91)70016-U","article-title":"Treatment of pyoderma gangrenosum with cyclosporine: results in seven patients","volume":"24","author":"Elgart","year":"1991","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2026.08.086_bib19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.jaad.2026.08.086_bib20","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaad.2016.06.016","article-title":"Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: a prospective cohort study","volume":"75","author":"Thomas","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2026.08.086_bib21","first-page":"361","article-title":"Pyoderma gangrenosum among patients with inflammatory bowel disease: a descriptive cohort Study","volume":"18","author":"Weizman","year":"2014","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.jaad.2026.08.086_bib22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7861\/clinmedicine.19-3-224","article-title":"Pyoderma gangrenosum - a guide to diagnosis and management","volume":"19","author":"George","year":"2019","journal-title":"Clin Med (Lond)"},{"issue":"8","key":"10.1016\/j.jaad.2026.08.086_bib23","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1111\/j.1572-0241.2003.07581.x","article-title":"Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease","volume":"98","author":"Regueiro","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"23","key":"10.1016\/j.jaad.2026.08.086_bib24","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1001\/jama.2021.21316","article-title":"Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial","volume":"326","author":"Syversen","year":"2021","journal-title":"Jama"},{"issue":"8","key":"10.1016\/j.jaad.2026.08.086_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/iwj.70733","article-title":"Treatments for pyoderma gangrenosum: a systematic review and single-arm meta-analysis of systemic therapies","volume":"22","author":"Kaur","year":"2025","journal-title":"Int Wound J"},{"issue":"12","key":"10.1016\/j.jaad.2026.08.086_bib26","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/1346-8138.15533","article-title":"Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Twenty-six-week phase 3 open-label study","volume":"47","author":"Yamasaki","year":"2020","journal-title":"J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2026.08.086_bib27","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/ecco-jcc\/jjaa078","article-title":"Inflammatory cutaneous lesions in inflammatory bowel disease treated with vedolizumab or ustekinumab: an ECCO CONFER multicentre case series","volume":"14","author":"Phillips","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaad.2026.08.086_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221102283","article-title":"Targeting IL12\/23 in ulcerative colitis: update on the role of ustekinumab","volume":"15","author":"Pugliese","year":"2022","journal-title":"Ther Adv Gastroenterol"},{"issue":"Suppl 2","key":"10.1016\/j.jaad.2026.08.086_bib29","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2024-334395","article-title":"British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025","volume":"74","author":"Moran","year":"2025","journal-title":"Gut"},{"issue":"20","key":"10.1016\/j.jaad.2026.08.086_bib30","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"New Engl J Med"},{"issue":"10","key":"10.1016\/j.jaad.2026.08.086_bib31","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/archdermatol.2011.168","article-title":"Interleukin 23 expression in pyoderma Gangrenosum and targeted therapy with ustekinumab","volume":"147","author":"Guenova","year":"2011","journal-title":"Arch Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2026.08.086_bib32","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/apt.15766","article-title":"Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease","volume":"51","author":"Wang","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jaad.2026.08.086_bib33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jdcr.2017.01.012","article-title":"Intractable pyoderma gangrenosum in a Crohn's disease patient on vedolizumab","volume":"3","author":"Yeh","year":"2017","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.jaad.2026.08.086_bib34","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10620-018-4971-1","article-title":"Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease","volume":"63","author":"Fleisher","year":"2018","journal-title":"Dig Dis Sci"},{"issue":"9","key":"10.1016\/j.jaad.2026.08.086_bib35","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/jgh.16612","article-title":"The impact of vedolizumab therapy on extraintestinal manifestations in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"39","author":"Zheng","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jaad.2026.08.086_bib36","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.cgh.2018.10.047","article-title":"Tofacitinib for the treatment of pyoderma gangrenosum","volume":"17","author":"Kochar","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.08.086_bib37","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/ced.14683","article-title":"Tofacitinib for the treatment of refractory pyoderma gangrenosum","volume":"46","author":"Orfaly","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.08.086_bib38","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.14309\/ajg.0000000000003463","article-title":"ACG Clinical Guideline update: ulcerative colitis in adults","volume":"120","author":"Rubin","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.jaad.2026.08.086_bib39","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001531","article-title":"Successful treatment of severe pyoderma gangrenosum and ulcerative colitis with upadacitinib","volume":"11","author":"Park","year":"2024","journal-title":"ACG Case Rep J"},{"key":"10.1016\/j.jaad.2026.08.086_bib40","doi-asserted-by":"crossref","DOI":"10.1177\/17562848261424321","article-title":"Successful treatment of severe retroauricular pyoderma gangrenosum with upadacitinib in a patient with Crohn's disease and a history of cerebral venous sinus thrombosis","volume":"19","author":"Fousekis","year":"2026","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.jaad.2026.08.086_bib41","article-title":"Case Report: treatment of facial pyoderma gangrenosum with Upadacitinib","volume":"12","author":"Ge","year":"2025","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.jaad.2026.08.086_bib42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00281-025-01064-7","article-title":"Pyoderma gangrenosum: pathogenetic mechanisms and their implications for treatment","volume":"47","author":"Moltrasio","year":"2025","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jaad.2026.08.086_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2026.01.017","article-title":"Ustekinumab and Janus kinase inhibitors outperform Vedolizumab as second-line therapy in anti-tumor necrosis factor-experienced patients with ulcerative colitis","author":"Privitera","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.jaad.2026.08.086_bib44","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1007\/s10067-021-05768-7","article-title":"Inflammatory arthritis-associated pyoderma gangrenosum: a systematic review","volume":"40","author":"Sawka","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.08.086_bib45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/mrcr\/rxac023","article-title":"Successful switching treatment of adalimumab for refractory pyoderma gangrenosum in a patient with rheumatoid arthritis with prior use of tumour necrosis factor inhibitors: a case report and review of the literature","volume":"7","author":"Ohmura","year":"2023","journal-title":"Mod Rheumatol Case Rep"},{"issue":"2","key":"10.1016\/j.jaad.2026.08.086_bib46","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1111\/jdv.13736","article-title":"Use of tocilizumab in a patient with pyoderma gangrenosum and rheumatoid arthritis","volume":"31","author":"Lee","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2026.08.086_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/exd.14954","article-title":"What can inherited immunodeficiencies reveal about pyoderma gangrenosum?","volume":"33","author":"Oprea","year":"2024","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2026.08.086_bib48","first-page":"97","article-title":"Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives","volume":"9","author":"Ly","year":"2019","journal-title":"Psoriasis (Auckl)"},{"issue":"8","key":"10.1016\/j.jaad.2026.08.086_bib49","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/ijd.16676","article-title":"JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum","volume":"62","author":"Castro","year":"2023","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2026.08.086_bib50","article-title":"Use of Baricitinib in a patient with treatment-resistant pyoderma gangrenosum","volume":"12","author":"Bechard","year":"2024","journal-title":"SAGE Open Med Case Rep"},{"issue":"7","key":"10.1016\/j.jaad.2026.08.086_bib51","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15275","article-title":"Case report: peristomal pyoderma gangrenosum complicated by rheumatoid arthritis and Beh\u00e7et's disease successfully treated with baricitinib","volume":"27","author":"Ito","year":"2024","journal-title":"Int J Rheum Dis"},{"issue":"10093","key":"10.1016\/j.jaad.2026.08.086_bib52","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2026.08.086_bib53","article-title":"Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: a systematic review and meta-analysis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2026.08.086_bib54","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.2024.20917","article-title":"Axial spondyloarthritis: a review","volume":"333","author":"Bittar","year":"2025","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jaad.2026.08.086_bib55","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s00296-024-05560-1","article-title":"Tofacitinib therapy for severe pyoderma gangrenosum in a patient with enteropathic arthritis: a case-based review","volume":"44","author":"K\u00f6ken Av\u015far","year":"2024","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.jaad.2026.08.086_bib56","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/exd.14534","article-title":"Pyoderma gangrenosum: a systematic review of the molecular characteristics of disease","volume":"31","author":"Flora","year":"2022","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2026.08.086_bib57","article-title":"Pyoderma gangrenosum treated with secukinumab: A case report","volume":"8","author":"McPhie","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"issue":"1","key":"10.1016\/j.jaad.2026.08.086_bib58","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00403-024-03689-4","article-title":"Anti-IL 17 biologics and pyoderma gangrenosum - therapeutic or causal?","volume":"317","author":"Wanzenberg","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2026.08.086_bib59","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241299564","article-title":"Psoriasis and inflammatory bowel disease: concomitant IMID or paradoxical therapeutic effect? A scoping review on anti-IL-12\/23 and anti-IL-23 antibodies","volume":"17","author":"Bezzio","year":"2024","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.jaad.2026.08.086_bib60","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jdcr.2021.11.030","article-title":"Modified dose of guselkumab for treatment of pyoderma gangrenosum","volume":"21","author":"Reese","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2026.08.086_bib61","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jdcr.2020.12.005","article-title":"Guselkumab as a treatment option for recalcitrant pyoderma gangrenosum","volume":"8","author":"Baier","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"10230","key":"10.1016\/j.jaad.2026.08.086_bib62","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaad.2026.08.086_bib63","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.jid.2024.10.602","article-title":"The clinical and molecular response of pyoderma gangrenosum to IL-23 blockade: result from a proof-of-concept open-label clinical trial","volume":"145","author":"Flora","year":"2025","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2026.08.086_bib64","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf144","article-title":"Practical considerations for the use of IL-23p19 inhibitors in inflammatory bowel disease: how to choose between them and why it matters?","volume":"19","author":"Pugliano","year":"2025","journal-title":"J Crohns Colitis"},{"issue":"10463","key":"10.1016\/j.jaad.2026.08.086_bib65","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0140-6736(24)01750-1","article-title":"IL-23 inhibition for chronic inflammatory disease","volume":"404","author":"Jairath","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2026.08.086_bib66","doi-asserted-by":"crossref","DOI":"10.1111\/ijd.70430","article-title":"Selective IL-23 inhibition in conventional treatment-refractory pyoderma gangrenosum: a multicenter, retrospective Study","author":"Bettolini","year":"2026","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2026.08.086_bib67","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jdcr.2017.02.019","article-title":"Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum","volume":"3","author":"Laird","year":"2017","journal-title":"JAAD Case Rep"},{"issue":"6","key":"10.1016\/j.jaad.2026.08.086_bib68","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.jaad.2019.09.032","article-title":"Pyoderma gangrenosum in hematologic malignancies: a systematic review","volume":"82","author":"Montagnon","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.08.086_bib69","article-title":"Hematological malignancy-associated pyoderma gangrenosum: evaluating the magnitude of the association","volume":"11","author":"Kridin","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.jaad.2026.08.086_bib70","first-page":"73","article-title":"Cutaneous manifestations of internal malignancy","volume":"59","author":"Thiers","year":"2009","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.jaad.2026.08.086_bib71","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1034\/j.1600-0560.2003.00024.x","article-title":"Pyoderma gangrenosum: a review","volume":"30","author":"Crowson","year":"2003","journal-title":"J Cutan Pathol"},{"issue":"3","key":"10.1016\/j.jaad.2026.08.086_bib72","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2174\/1381612053382179","article-title":"Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation","volume":"11","author":"Yasui","year":"2005","journal-title":"Curr Pharm Des"},{"issue":"5 Pt 1","key":"10.1016\/j.jaad.2026.08.086_bib73","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0190-9622(08)80705-0","article-title":"Pyoderma gangrenosum associated with Beh\u00e7et's disease: treatment with thalidomide","volume":"23","author":"Rustin","year":"1990","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2026.08.086_bib74","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1080\/10428190701361224","article-title":"IgG multiple myeloma presented with ulcerative pyoderma gangrenosum","volume":"48","author":"Verrou","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.jaad.2026.08.086_bib75","doi-asserted-by":"crossref","first-page":"842","DOI":"10.4065\/75.8.842","article-title":"Recalcitrant pyoderma gangrenosum treated with thalidomide","volume":"75","author":"Federman","year":"2000","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.jaad.2026.08.086_bib76","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/1078155214541975","article-title":"Pyoderma gangrenosum due to lenalidomide use for multiple myeloma","volume":"21","author":"Dasanu","year":"2015","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"10.1016\/j.jaad.2026.08.086_bib77","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00277-019-03846-0","article-title":"Pyoderma gangrenosum induced by lenalidomide in a case of multiple myeloma","volume":"99","author":"Meunier","year":"2020","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.jaad.2026.08.086_bib78","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1111\/iwj.12746","article-title":"Dramatic resolution of disseminated pyoderma gangrenosum associated with monoclonal gammopathy after therapy with bortezomib and dexamethasone","volume":"14","author":"Velasco-Tamariz","year":"2017","journal-title":"Int Wound J"},{"issue":"5","key":"10.1016\/j.jaad.2026.08.086_bib79","doi-asserted-by":"crossref","DOI":"10.5070\/D3265048791","article-title":"The dilemma of treating pyoderma gangrenosum associated with monoclonal gammopathy of undetermined significance","volume":"26","author":"Machan","year":"2020","journal-title":"Dermatol Online J"},{"issue":"1","key":"10.1016\/j.jaad.2026.08.086_bib80","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40257-024-00904-w","article-title":"Intravenous immunoglobulin therapy for pyoderma gangrenosum: a multicenter retrospective analysis in 81 patients","volume":"26","author":"Ronicke","year":"2025","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.08.086_bib81","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjd.15850","article-title":"Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series","volume":"178","author":"Song","year":"2018","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2026.08.086_bib82","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1007\/s00296-023-05418-y","article-title":"Quantitative analysis of JAK\/STAT signaling pathway in patients of inflammatory skin disorders","volume":"44","author":"Demirci Yildirim","year":"2024","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.jaad.2026.08.086_bib83","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40257-017-0265-1","article-title":"PAPA, PASH and PAPASH syndromes: pathophysiology, presentation and treatment","volume":"18","author":"Cugno","year":"2017","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2026.08.086_bib84","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/rheumatology\/kew031","article-title":"Disease activity accounts for long-term efficacy of IL-1 blockers in pyogenic sterile arthritis pyoderma gangrenosum and severe acne syndrome","volume":"55","author":"Omenetti","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.jaad.2026.08.086_bib85","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1136\/annrheumdis-2018-213746","article-title":"Dysregulated neutrophil responses and neutrophil extracellular trap formation and degradation in PAPA syndrome","volume":"77","author":"Mistry","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.jaad.2026.08.086_bib86","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1365-2133.2009.09404.x","article-title":"Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra","volume":"161","author":"Brenner","year":"2009","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2026.08.086_bib87","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/ced.14809","article-title":"Anakinra for recalcitrant pyoderma gangrenosum","volume":"46","author":"O'Connor","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2026.08.086_bib88","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/bjd.14037","article-title":"Canakinumab in adults with steroid-refractory pyoderma gangrenosum","volume":"173","author":"Kolios","year":"2015","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2026.08.086_bib89","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jdcr.2016.07.007","article-title":"The role of interleukin-1\u03b2 in pyoderma gangrenosum","volume":"2","author":"Galimberti","year":"2016","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.jaad.2026.08.086_bib90","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/jvc2.52","article-title":"The efficacy of anti-IL-1 targeted therapy in PAPA and PASH syndrome","volume":"1","author":"Challamel","year":"2022","journal-title":"JEADV Clin Pract"},{"issue":"11","key":"10.1016\/j.jaad.2026.08.086_bib91","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1111\/jdv.12765","article-title":"Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone","volume":"29","author":"Staub","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2026.08.086_bib92","article-title":"A child with recurrent pyogenic arthritis with the PSTPIP1 mutation","volume":"8","author":"Guo","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"issue":"18","key":"10.1016\/j.jaad.2026.08.086_bib93","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa013383","article-title":"Skin ulcers misdiagnosed as pyoderma gangrenosum","volume":"347","author":"Weenig","year":"2002","journal-title":"New Engl J Med"},{"issue":"7","key":"10.1016\/j.jaad.2026.08.086_bib94","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMra2305712","article-title":"Beh\u00e7et\u2019s syndrome","volume":"390","author":"Saadoun","year":"2024","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jaad.2026.08.086_bib95","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et's disease: multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J Autoimmun"},{"issue":"5","key":"10.1016\/j.jaad.2026.08.086_bib96","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1093\/rheumatology\/keae585","article-title":"Infliximab vs interferon-\u03b1 in the treatment of Beh\u00e7et's syndrome: clinical data from the BIO-BEH\u00c7ET'S randomized controlled trial","volume":"64","author":"Moots","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.jaad.2026.08.086_bib97","first-page":"CD011018","article-title":"Interventions for the management of oral ulcers in Beh\u00e7et\u2019s disease","volume":"2014","author":"Taylor","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.jaad.2026.08.086_bib98","first-page":"69","article-title":"Apremilast in refractory orogenital ulcers and other manifestations of Beh\u00e7et's disease. A national multicentre study of 51 cases in clinical practice","volume":"38 Suppl 127","author":"Atienza-Mateo","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2026.08.086_bib99","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jdcr.2022.10.001","article-title":"Treatment of pyoderma gangrenosum with apremilast monotherapy","volume":"30","author":"Bordeaux","year":"2022","journal-title":"JAAD Case Rep"},{"issue":"7","key":"10.1016\/j.jaad.2026.08.086_bib100","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/09273948.2017.1421233","article-title":"Use of gevokizumab in patients with Beh\u00e7et's Disease uveitis: an international, randomized, Double-Masked, placebo-controlled Study and open-label extension Study","volume":"26","author":"Tugal-Tutkun","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jaad.2026.08.086_bib101","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keag086","article-title":"The use of non-TNF targeted biologics in Beh\u00e7et's Disease: Real-life data from the International AIDA Network Beh\u00e7et's Disease Registry","author":"Sevik","year":"2026","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2026.08.086_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.869466","article-title":"Autoimmune cytopenias in common variable immunodeficiency are a diagnostic and therapeutic conundrum: an update","volume":"13","author":"Chawla","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2026.08.086_bib103","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12728","article-title":"Common variable immune deficiency: dissection of the variable","volume":"287","author":"Cunningham-Rundles","year":"2019","journal-title":"Immunol Rev"},{"issue":"30","key":"10.1016\/j.jaad.2026.08.086_bib104","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA Clinical Practice Guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2026.08.086_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.606389","article-title":"What works when treating granulomatous disease in genetically undefined CVID? A systematic review","volume":"11","author":"van Stigt","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2026.08.086_bib106","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2141.2011.08880.x","article-title":"Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients","volume":"155","author":"Gobert","year":"2011","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jaad.2026.08.086_bib107","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40257-017-0308-7","article-title":"Drug-Induced pyoderma gangrenosum: a review","volume":"19","author":"Wang","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.08.086_bib108","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bjd.15193","article-title":"Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum","volume":"177","author":"Wu","year":"2017","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2026.08.086_bib109","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-4632.2008.03662.x","article-title":"Pyoderma gangrenosum following isotretinoin therapy for acne nodulocystic","volume":"47","author":"Tinoco","year":"2008","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2026.08.086_bib110","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1046\/j.1525-1470.2001.01969.x","article-title":"Neutrophilic dermatoses in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor (G-CSF) therapy","volume":"18","author":"Prendiville","year":"2001","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2026.08.086_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101516","article-title":"G-CSF - a double edge sword in neutrophil mediated immunity","volume":"54","author":"Martin","year":"2021","journal-title":"Semin Immunol"},{"issue":"8","key":"10.1016\/j.jaad.2026.08.086_bib112","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/cup.13687","article-title":"Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: a case series","volume":"47","author":"Morris","year":"2020","journal-title":"J Cutan Pathol"},{"issue":"1","key":"10.1016\/j.jaad.2026.08.086_bib113","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/cup.14740","article-title":"Pyoderma gangrenosum associated with iatrogenic interleukin 17A blockade: a report of two cases and a review of the literature","volume":"53","author":"Magro","year":"2026","journal-title":"J Cutan Pathol"},{"issue":"6","key":"10.1016\/j.jaad.2026.08.086_bib114","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.jaad.2026.08.086_bib115","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/pde.15828","article-title":"Rapidly progressive idiopathic pyoderma gangrenosum in a pediatric patient successfully treated with infliximab","volume":"42","author":"Perry","year":"2025","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2026.08.086_bib116","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/wrr.12910","article-title":"The role of negative pressure wound therapy (NPWT) on the treatment of pyoderma gangrenosum: a systematic review and personal experience","volume":"29","author":"Almeida","year":"2021","journal-title":"Wound Repair Regen"},{"issue":"3","key":"10.1016\/j.jaad.2026.08.086_bib117","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13412","article-title":"PG-TIME: a practical approach to the clinical management of pyoderma gangrenosum","volume":"33","author":"Janowska","year":"2020","journal-title":"Dermatol Ther"},{"issue":"23","key":"10.1016\/j.jaad.2026.08.086_bib118","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11236924","article-title":"Treatment strategy for pyoderma gangrenosum: skin grafting with immunosuppressive drugs","volume":"11","author":"Nishimura","year":"2022","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.jaad.2026.08.086_bib119","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1474-4422(25)00068-7","article-title":"Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis","volume":"24","author":"Soliman","year":"2025","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.jaad.2026.08.086_bib120","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0190-9622(87)80370-5","article-title":"Cromolyn sodium in 2% aqueous solution under an occlusive hydrocolloid dressing may be effective adjunctive treatment in management of pyoderma gangrenosum","volume":"17","author":"Smith","year":"1987","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.08.086_bib121","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000359974","article-title":"Niacinamide - mechanisms of action and its topical use in dermatology","volume":"27","author":"Wohlrab","year":"2014","journal-title":"Skin Pharmacol Physiol"},{"issue":"3","key":"10.1016\/j.jaad.2026.08.086_bib122","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s40257-025-00999-9","article-title":"Past, present, and future of sodium hypochlorite in dermatology: a scoping review","volume":"27","author":"Chang","year":"2026","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2026.08.086_bib123","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.1624","article-title":"Effect of stabilized hypochlorous acid on Re-epithelialization and bacterial bioburden in acute wounds: a randomized controlled trial in healthy volunteers","volume":"102","author":"Burian","year":"2022","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2026.08.086_bib124","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/s41598-018-19879-w","article-title":"Novel mechanisms of Collagenase Santyl Ointment (CSO) in wound macrophage polarization and resolution of wound inflammation","volume":"8","author":"Das","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.jaad.2026.08.086_bib125","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/wrr.12882","article-title":"Efficacy and safety of skin grafting in treatment of vasculitic ulcer and pyoderma gangrenosum-A systematic review","volume":"29","author":"Morgenstjerne-Schwenck","year":"2021","journal-title":"Wound Repair Regen"},{"issue":"6","key":"10.1016\/j.jaad.2026.08.086_bib126","doi-asserted-by":"crossref","DOI":"10.1111\/iwj.14943","article-title":"The role of split-thickness skin grafting in the treatment of vasculitic and pyoderma gangrenosum ulcers in a multidisciplinary wound centre","volume":"21","author":"Suoniemi","year":"2024","journal-title":"Int Wound J"},{"issue":"12","key":"10.1016\/j.jaad.2026.08.086_bib127","first-page":"1214","article-title":"Pyoderma gangrenosum: dermatologic application of hyperbaric oxygen therapy","volume":"6","author":"Tutrone","year":"2007","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2026.08.086_bib128","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1742-481X.2012.01102.x","article-title":"A favourable response to surgical intervention and hyperbaric oxygen therapy in pyoderma gangrenosum","volume":"11","author":"Altunay","year":"2014","journal-title":"Int Wound J"},{"key":"10.1016\/j.jaad.2026.08.086_bib129","unstructured":"A Multi-centre, Randomised, Placebo-controlled, Double-blind, Parallel-group Trial to Evaluate Safety and Efficacy of Spesolimab (BI 655130) in Adult Patients With Ulcerative Pyoderma Gangrenosum (PG) Who Require Systemic Therapy."},{"issue":"6","key":"10.1016\/j.jaad.2026.08.086_bib130","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jid.2024.12.023","article-title":"The Changing Landscape of Clinical Research in Pyoderma Gangrenosum","volume":"145","author":"Becker","year":"2025","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2026.08.086_bib131","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jdcr.2026.02.026","article-title":"Successful use of spesolimab in refractory pyoderma gangrenosum","volume":"70","author":"Lum","year":"2026","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.jaad.2026.08.086_bib132","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s13555-024-01325-7","article-title":"Analysis of predefined safety events across spesolimab trials in dermatological and non-dermatological conditions","volume":"15","author":"Gordon","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2026.08.086_bib133","unstructured":"A Single-arm Open-label Study Assessing Short-term (Week 6, 16) and Long-term (Week 32) Efficacy of Guselkumab in Adult Participants With Pyoderma Gangrenosum."},{"issue":"5","key":"10.1016\/j.jaad.2026.08.086_bib134","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/1346-8138.16337","article-title":"Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: final analysis of a 52-week phase 3 open-label study","volume":"49","author":"Yamasaki","year":"2022","journal-title":"J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2026.08.086_bib135","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1111\/1346-8138.16845","article-title":"Clinical guidance of pyoderma gangrenosum 2022","volume":"50","author":"Yamamoto","year":"2023","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.08.086_bib136","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00403-025-03920-w","article-title":"Pyoderma gangrenosum refined elements for core item selection and evaluation (PRECISE-PG): a study protocol for reaching consensus on core outcome domain items in clinical trials of pyoderma gangrenosum","volume":"317","author":"Tobey","year":"2025","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"10.1016\/j.jaad.2026.08.086_bib137","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/bjd\/ljad420","article-title":"A core domain set for pyoderma gangrenosum trial outcomes: an international eDelphi and consensus study from the UPGRADE initiative","volume":"190","author":"Jacobson","year":"2024","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2026.08.086_bib138","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1007\/s00403-023-02729-9","article-title":"Minimum data set for treatment effectiveness in pyoderma gangrenosum (MIDSTEP): an international protocol of an e-Delphi study to develop a clinical physician-driven treatment effectiveness registry on behalf of the UPGRADE initiative","volume":"315","author":"Haddadin","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2026.08.086_bib139","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2026.0859","article-title":"The national psoriasis foundation primer on GLP-1 receptor agonists in psoriasis: a review","author":"Sheth","year":"2026","journal-title":"JAMA Dermatol"},{"issue":"21","key":"10.1016\/j.jaad.2026.08.086_bib140","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194751","article-title":"Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits","volume":"135","author":"Wong","year":"2025","journal-title":"J Clin Invest"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226034080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226034080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:27:51Z","timestamp":1793370471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226034080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":140,"alternative-id":["S0190962226034080"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.08.086","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comorbidity-guided management of pyoderma gangrenosum: A clinical guide to emerging therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.08.086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}